Skip to main content
SpringerLink
Log in

Burden of Migraine

A Review of its Socioeconomic Impact

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

According to population-based epidemiological studies using International Headache Society diagnostic criteria, the prevalence of migraine in developed countries ranges from 8 to 14%. These prevalence figures confirm the widespread nature of the disorder. Moreover, as migraine is a chronic episodic disorder that predominantly affects people during their working lives (between the ages of 25 and 55 years), indirect costs associated with reduced productivity represent a substantial proportion of the total cost of migraine.

The results of health-related quality-of-Life studies demonstrate that migraine has a considerable impact on functional capacity, resulting in disrupted work and social activities. Many migraineurs, however, do not seek medical attention, have not been accurately diagnosed by a physician or do not use prescription medication. Therefore, the direct costs of treatment for migraine are relatively small compared with the indirect costs.

Migraine is an important chronic illness that has a major impact on the working sector of a population. The overall cost attributable to migraine is unknown, but it is now established that the indirect costs of migraine outweigh the direct costs and therefore represent an obvious target for healthcare intervention aimed at reducing the impact of this chronic condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart WF, Lipton RB, Celentano DO, et al. Prevalence ofmigraine headache in the United States. JAMA 1992; 267:64–9

    Article  PubMed  CAS  Google Scholar 

  2. Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic and societal impactof migraine and tension-type headache. Can J Neurol Sci1992; 19: 333–9

    PubMed  CAS  Google Scholar 

  3. International Headache Society (IHS). Headache Classification Committee of the IHS. Classification and diagnostic criteriafor headache disorders, cranial neuralgias, and facial pain.Cephalalgia 1988; 8 Suppl. 7: 1–96

    Google Scholar 

  4. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology 1994; 44Suppl. 7: 17–22

    Google Scholar 

  5. Blau IN.Migraine: theories of pathogenesis. Lancet 1992; 339: 1202–7

    Article  PubMed  CAS  Google Scholar 

  6. Merikangas KR. Genetic epidemiology of migraine. In: Sandler M, Collins GM, editors. Migraine: a spectrum of ideas. Oxford University Press, 1990: 40–50

    Chapter  Google Scholar 

  7. Bartelink ML, van Weel C. Migraine in female patients in family practice. Headache Quarterly 1995; 6: 203–7

    Google Scholar 

  8. Lipton RB, Silberstein SO, Stewart WF. An update on the epidemiology of migraine. Headache 1994; 34: 319–28

    Article  PubMed  CAS  Google Scholar 

  9. Stewart WF, Simon O, Shecter A, et al. Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995;48: 269–80

    Article  PubMed  CAS  Google Scholar 

  10. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34 Suppl. 2: 6–11

    Article  Google Scholar 

  11. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131–7

    PubMed  CAS  Google Scholar 

  12. Stang PE, Osterhaus JT, Celetano DO. Migraine: patterns of healthcare use. Neurology 1994; 44 Suppl. 4: S47–55

    Google Scholar 

  13. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and healthcare use. Neurology 1993; 43Suppl. 3: 6–10

    Google Scholar 

  14. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of youngadults. Psychiatry Res 1991; 37: 11–23

    Article  PubMed  CAS  Google Scholar 

  15. Cull RA, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15

    Google Scholar 

  16. Henry P, Michel P, Brochet B, et al. A nationwide survey of migraine in France: prevalence and clinical features in adults.Cephalalgia 1992; 12: 229–37

    Article  PubMed  CAS  Google Scholar 

  17. Michel P, Pariente P, Duru G, et al. MIG ACCESS: a population- based, nationwide, comparative survey of access to carein migraine in France. Cephalalgia 1995; 16: 50–5

    Article  Google Scholar 

  18. Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population: a prevalence study. J ClinEpidemiol 1991; 44: 1147–57

    Article  PubMed  CAS  Google Scholar 

  19. van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Societal perspective on the burden of migraine in The Netherlands.Pharmaco Economics 1995; 7: 170–9

    Article  Google Scholar 

  20. Action Asthma. The occurrence and cost of asthma. Worthing: Cambridge Medical Publications, 1990 (ISBN: 0904052028)

  21. British Diabetic Association (BOA). Diabetes in the United Kingdom. London: BOA, 1988

    Google Scholar 

  22. Office of Health Economics (OHE). Epilepsy. London: OHE,1991

    Google Scholar 

  23. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15

    Google Scholar 

  24. Stewart WF, Linet MA, Celentano DO, et al. Age and sex-specific incidence rates of migraine with and without visual aura.Am J Epidemiol 1991; 34: 1111–20

    Google Scholar 

  25. MacGregor EA. Menstrual migraine: towards a definition. Cephalalgia 1996; 16: 11–21

    Article  PubMed  CAS  Google Scholar 

  26. Silberstein SO. The role of sex hormones in headache. Neurology 1992; 42 Suppl. 2: 37–42

    Google Scholar 

  27. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994; 309: 765–9

    Article  PubMed  CAS  Google Scholar 

  28. Raieli V, Raimondo O, Cammalleri R, et al. Migraine headaches in adolescents: a student population-based study in Monreale.Cephalalgia 1995; 15: 5–12

    Article  PubMed  CAS  Google Scholar 

  29. Lipton RB, Stewart WF, Von Korff M. Migraine impact and functional disability. Cephalalgia 1995; Suppl. 15: 4–9

    Google Scholar 

  30. Von Korff M, Ormel J, Keefe F, et al. Grading the severity of chronic pain. Pain 1992; 50: 133–49

    Article  Google Scholar 

  31. Patrick DL, Erickson P. Health status and health policy: quality of life in healthcare evaluation and resource allocation. NewYork: Oxford University Press, 1992

    Google Scholar 

  32. Hartmaier SL, Santanello N, Epstein RS, et al. Development of a brief 24-hour migraine-specific quality of life questionnaire.Headache 1995; 35: 320–9

    Article  PubMed  CAS  Google Scholar 

  33. Miller DW, Kirchdoerfer LJ, Sheperd MO, et al. Adisease-spe-cific instrument to measure quality of life effects attributableto migraine. Health Service Research Association 10th Annual Meeting: 1993 June 27-29, Washington DC

    Google Scholar 

  34. Richard A, Henry P, Chazot G, et al. Qualite de vie et migraine. Validation du questionnaire QVM en consultationhospitaliere et en medecine generale. Therapie 1993; 48:89–96

    PubMed  CAS  Google Scholar 

  35. Santanello NC, Hartmaier SL, Epstein SL, et al. Validation of a new quality of life questionnaire for acute migraine headache.Headache 1995; 35: 330–7

    Article  PubMed  CAS  Google Scholar 

  36. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional stalUs and well-being of patients with migraineheadache. Headache 1994; 34: 337–43

    Article  PubMed  CAS  Google Scholar 

  37. Essink-Bot ML, van Royen L, Krabbe P, et al. The impact of migraine on health status. Headache 1995; 35: 200–6

    Article  PubMed  CAS  Google Scholar 

  38. Tarlov AR, Ware JE, Greenfield S, et al. The medical outcomes study. An application of methods for monitoring the results of medical care. JAMA 1989; 262: 925–30

    Article  PubMed  CAS  Google Scholar 

  39. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic medical conditions. Results from the medical outcomes study. JAMA 1989; 262:907–13

    Article  PubMed  CAS  Google Scholar 

  40. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among beadacbe diagnoses? Analysis using tbe MedicalOutcomes Study Instrument. Headache 1994; 34: 143–7

    Article  PubMed  CAS  Google Scholar 

  41. Dahlöf CGH, Dimeneäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks.Cephalalgia 1995; 15: 31–6

    Article  PubMed  Google Scholar 

  42. Drummond M. Cost-of-illness studies. A major headache? Pharmaco Economics 1992; 2; 1–4

    Article  CAS  Google Scholar 

  43. Davey PJ, Leeder SR. The cost of migraine. More than just a headache? Pharmaco Economics 1992; 2: 5–7

    Article  CAS  Google Scholar 

  44. de Lissovoy G, Lazarus SS. The economic cost of migraine. Present state of knowledge. Neurology 1994; 44 Suppl. 4:56–62

    Google Scholar 

  45. Blau IN, Drummond MF. Migraine. Office of Health Economics OHE London: OHE, 1991

    Google Scholar 

  46. Ramussen BK. Epidemiology of headache. Cephalalgia 1995: 15: 45–68

    Google Scholar 

  47. Lipton RB, Stewan WF, Von Korff M. Individual and societal impact of migraine. In: Olesen J, editor. Headache classification and epidemiology. New York: Raven Press, 1994: 327–33

    Google Scholar 

  48. Osterhaus JT. Gutterman DL. Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US.Pharmaco Economics 1992; 2: 67–76

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Headache, Department of General Internal Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    G. D. Solomon

  2. Glaxo Wellcome Research and Development, Pharmacoeconomic Research, Greenford, Middlesex, England

    K. L. Price

Authors
  1. G. D. Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. L. Price
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solomon, G.D., Price, K.L. Burden of Migraine. Pharmaco economics 11 (Suppl 1), 1–10 (1997). https://doi.org/10.2165/00019053-199700111-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199700111-00003

Keywords

Search

Navigation